{"pmid":32282268,"title":"Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?","text":["Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?","The last century has witnessed several assaults from RNA viruses, resulting in millions of death throughout the world. The 21st century appears no longer an exception, with the trend continued with escalated fear of SARS coronavirus in 2002 and further concern of influenza H5N1 in 2003. A novel influenza virus created the first pandemic of the 21st century, the pandemic flu in 2009 preceded with the emergence of another deadly virus, MERS-CoV in 2012. A novel coronavirus \"SARS-CoV-2\" (and the disease COVID-19) emerged suddenly, causing a rapid outbreak with a moderate case fatality rate. This virus is continuing to cause health care providers grave concern due to the lack of any existing immunity in the human population, indicating their novelty and lack of previous exposure. The big question is whether this novel virus will be establishing itself in an endemic form or will it eventually die out? Endemic viruses during circulation may acquire mutations to infect naive, as well as individual with pre-existing immunity. Continuous monitoring is strongly advisable, not only to the newly infected individuals, but also to those recovered individuals who were infected by SARS-CoV-2 as re-infection may lead to the selection of escape mutants and subsequent dissemination to the population.","Crit Rev Microbiol","Biswas, Asim","Bhattacharjee, Uttaran","Chakrabarti, Alok Kumar","Tewari, Devendra Nath","Banu, Hasina","Dutta, Shanta","32282268"],"abstract":["The last century has witnessed several assaults from RNA viruses, resulting in millions of death throughout the world. The 21st century appears no longer an exception, with the trend continued with escalated fear of SARS coronavirus in 2002 and further concern of influenza H5N1 in 2003. A novel influenza virus created the first pandemic of the 21st century, the pandemic flu in 2009 preceded with the emergence of another deadly virus, MERS-CoV in 2012. A novel coronavirus \"SARS-CoV-2\" (and the disease COVID-19) emerged suddenly, causing a rapid outbreak with a moderate case fatality rate. This virus is continuing to cause health care providers grave concern due to the lack of any existing immunity in the human population, indicating their novelty and lack of previous exposure. The big question is whether this novel virus will be establishing itself in an endemic form or will it eventually die out? Endemic viruses during circulation may acquire mutations to infect naive, as well as individual with pre-existing immunity. Continuous monitoring is strongly advisable, not only to the newly infected individuals, but also to those recovered individuals who were infected by SARS-CoV-2 as re-infection may lead to the selection of escape mutants and subsequent dissemination to the population."],"journal":"Crit Rev Microbiol","authors":["Biswas, Asim","Bhattacharjee, Uttaran","Chakrabarti, Alok Kumar","Tewari, Devendra Nath","Banu, Hasina","Dutta, Shanta"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282268","week":"202016|Apr 13 - Apr 19","doi":"10.1080/1040841X.2020.1739001","keywords":["COVID-19","Coronavirus","SARS","SARS-CoV-2","pre existing immunity"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663989232524328960,"score":7.979339,"similar":[{"pmid":32134278,"title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","text":["Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).","Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.","Asian Pac J Allergy Immunol","Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo","32134278"],"abstract":["Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen."],"journal":"Asian Pac J Allergy Immunol","authors":["Shanmugaraj, Balamurugan","Siriwattananon, Konlavat","Wangkanont, Kittikhun","Phoolcharoen, Waranyoo"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134278","week":"202010|Mar 02 - Mar 08","doi":"10.12932/AP-200220-0773","source":"PubMed","locations":["China","Wuhan","Chikungunya","Zika"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352134217760768,"score":258.4676},{"pmid":32143502,"title":"Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.","text":["Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks.","Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat.","Pathogens","Ashour, Hossam M","Elkhatib, Walid F","Rahman, Md Masudur","Elshabrawy, Hatem A","32143502"],"abstract":["Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat."],"journal":"Pathogens","authors":["Ashour, Hossam M","Elkhatib, Walid F","Rahman, Md Masudur","Elshabrawy, Hatem A"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32143502","week":"202010|Mar 02 - Mar 08","doi":"10.3390/pathogens9030186","keywords":["2019-nCoV","COVID-19","MERS","SARS","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Treatment","Mechanism"],"weight":1,"_version_":1663352134178963456,"score":257.08353},{"pmid":32250347,"title":"[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","text":["[Consensus Report from Turkish Society of Cardiology: COVID-19 and Cardiovascular Diseases. What cardiologists should know. (25th March 2020)].","In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered.","Turk Kardiyol Dern Ars","Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem","32250347"],"abstract":["In December 2019, in the city of Wuhan, in the Hubei province of China, treatment-resistant cases of pneumonia emerged and spread rapidly for reasons unknown. A new strain of coronavirus (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) was identified and caused the first pandemic of the 21st century. The virus was officially detected in our country on March 11, 2020, and the number of cases increased rapidly; the virus was isolated in 670 patients within 10 days. The rapid increase in the number of patients has required our physicians to learn to protect both the public and themselves when treating patients with this highly infectious disease. The group most affected by the outbreak and with the highest mortality rate is elderly patients with known cardiovascular disease. Therefore, it is necessary for cardiology specialists to take an active role in combating the epidemic. The aim of this article is to make a brief assessment of current information regarding the management of cardiovascular patients affected by COVID-19 and to provide practical suggestions to cardiology specialists about problems and questions they have frequently encountered."],"journal":"Turk Kardiyol Dern Ars","authors":["Aktoz, Meryem","Altay, Hakan","Aslanger, Emre","Atalar, Enver","Aytekin, Vedat","Baykan, Ahmet Oytun","Barcin, Cem","Baris, Nezihi","Boyaci, Asiye Ayca","Cavusoglu, Yuksel","Celik, Ahmet","Cinier, Goksel","Degertekin, Muzaffer","Ergonul, Onder","Erturk, Mehmet","Erol, M Kemal","Gorenek, Bulent","Gursoy, Mustafa Ozan","Hunuk, Burak","Kahveci, Gokhan","Karabay, Can Yucel","Karaca, Ilgin","Kayikcioglu, Meral","Keskin, Muhammed","Kilic, Teoman","Kirma, Cevat","Kocabas, Umut","Kucukoglu, Serdar","Mutlu, Bulent","Nalbantgil, Sanem","Okuyan, Ertugrul","Okyay, Kaan","Kaptan Ozen, Deniz","Ozgul, Sami","Ozpelit, Ebru","Pirat, Bahar","Sert, Sena","Sinan, Umit Yasar","Sener, Yusuf Ziya","Tatli, Ersan","Tekkesin, Ahmet Ilker","Tutar, Eralp","Ural, Dilek","Yildirimturk, Ozlem"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250347","week":"202015|Apr 06 - Apr 12","doi":"10.5543/tkda.2020.97198","source":"PubMed","locations":["China","Turkish","Wuhan","Hubei"],"countries":["China","Turkey"],"countries_codes":["CHN|China","TUR|Turkey"],"topics":["Prevention"],"weight":1,"_version_":1663352136221589507,"score":240.46765},{"pmid":32175703,"title":"COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia.","text":["COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia.","Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has plagued the Middle East since it was first reported in 2012. Recently, at the end of December 2019, a cluster of pneumonia cases were reported from Wuhan city, Hubei Province, China, linked to a wet seafood market with a new coronavirus identified as the etiologic agent currently named SARS-CoV-2. Most cases are in Mainland China with international spread to 25 countries. The novelty of the virus, the rapid national and international spread, and the lack of therapeutic and preventative strategies have led the WHO International Health Regulation emergency committee to declare the disease as Public Health Emergency of International Concern (PHEIC) on January 30, 2020. As it relates to countries with the ongoing MERS-CoV community cases and hospital acquired infections, there will be a huge challenge for HCWs to deal with both coronaviruses, especially with the lack of standardized and approved point of care testing. This challenge will now be faced by the whole global health community dealing with COVID-19 since both coronaviruses have similar presentation. Those patients should now be tested for both MERS-CoV and SARS-CoV-2 simultaneously, and with the continuing wide international spread of SARS-CoV-2, the travel history to China in the last 14 days will be of less significance.","J Epidemiol Glob Health","Barry, Mazin","Al Amri, Maha","Memish, Ziad A","32175703"],"abstract":["Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has plagued the Middle East since it was first reported in 2012. Recently, at the end of December 2019, a cluster of pneumonia cases were reported from Wuhan city, Hubei Province, China, linked to a wet seafood market with a new coronavirus identified as the etiologic agent currently named SARS-CoV-2. Most cases are in Mainland China with international spread to 25 countries. The novelty of the virus, the rapid national and international spread, and the lack of therapeutic and preventative strategies have led the WHO International Health Regulation emergency committee to declare the disease as Public Health Emergency of International Concern (PHEIC) on January 30, 2020. As it relates to countries with the ongoing MERS-CoV community cases and hospital acquired infections, there will be a huge challenge for HCWs to deal with both coronaviruses, especially with the lack of standardized and approved point of care testing. This challenge will now be faced by the whole global health community dealing with COVID-19 since both coronaviruses have similar presentation. Those patients should now be tested for both MERS-CoV and SARS-CoV-2 simultaneously, and with the continuing wide international spread of SARS-CoV-2, the travel history to China in the last 14 days will be of less significance."],"journal":"J Epidemiol Glob Health","authors":["Barry, Mazin","Al Amri, Maha","Memish, Ziad A"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32175703","week":"202012|Mar 16 - Mar 22","doi":"10.2991/jegh.k.200218.003","keywords":["*COVID-19","*MERS-CoV","*SARS-CoV-2","*Saudi Arabia"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1663352133892702209,"score":223.09396},{"pmid":32129518,"title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","text":["Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.","Drug Dev Res","Gurwitz, David","32129518"],"abstract":["At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility."],"journal":"Drug Dev Res","authors":["Gurwitz, David"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129518","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ddr.21656","keywords":["AT1R blockers","COVID-19 epidemic","SARS-CoV-2","angiotensin-converting enzyme 2 (ACE2)","losartan"],"source":"PubMed","locations":["losartan"],"topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Losartan"],"_version_":1663352134262849536,"score":209.66396}]}